中国药物经济学
中國藥物經濟學
중국약물경제학
CHINA JOURNAL OF PHARMACEUTICAL ECONOMICS
2015年
2期
188-189
,共2页
抗肿瘤药物%药剂科%安全管理%临床用药
抗腫瘤藥物%藥劑科%安全管理%臨床用藥
항종류약물%약제과%안전관리%림상용약
Antineoplastic drugs%Pharmacy department%Safety management%Clinical medicine
目的:探讨药剂科规范抗肿瘤药物安全管理的必要性,为安全合理的使用抗肿瘤药物提供依据。方法以236例肿瘤患者作为对照组,采用传统药物安全管理模式;另取256例肿瘤患者为试验组,采用规范抗肿瘤药物安全管理模式。比较两组患者的治疗情况和不良反应发生率。结果对照组患者平均住院时间、用药种类和治疗费用均高于试验组;对照组患者不良反应发生率为50.4%,试验组患者不良反应发生率为35.5%,差异有统计学意义(P<0.05)。结论对抗肿瘤药物展开安全管理,可明显缩短患者住院时间,降低治疗费用,减少不良反应,提高疗效,实现真正的安全合理用药。
目的:探討藥劑科規範抗腫瘤藥物安全管理的必要性,為安全閤理的使用抗腫瘤藥物提供依據。方法以236例腫瘤患者作為對照組,採用傳統藥物安全管理模式;另取256例腫瘤患者為試驗組,採用規範抗腫瘤藥物安全管理模式。比較兩組患者的治療情況和不良反應髮生率。結果對照組患者平均住院時間、用藥種類和治療費用均高于試驗組;對照組患者不良反應髮生率為50.4%,試驗組患者不良反應髮生率為35.5%,差異有統計學意義(P<0.05)。結論對抗腫瘤藥物展開安全管理,可明顯縮短患者住院時間,降低治療費用,減少不良反應,提高療效,實現真正的安全閤理用藥。
목적:탐토약제과규범항종류약물안전관리적필요성,위안전합리적사용항종류약물제공의거。방법이236례종류환자작위대조조,채용전통약물안전관리모식;령취256례종류환자위시험조,채용규범항종류약물안전관리모식。비교량조환자적치료정황화불량반응발생솔。결과대조조환자평균주원시간、용약충류화치료비용균고우시험조;대조조환자불량반응발생솔위50.4%,시험조환자불량반응발생솔위35.5%,차이유통계학의의(P<0.05)。결론대항종류약물전개안전관리,가명현축단환자주원시간,강저치료비용,감소불량반응,제고료효,실현진정적안전합리용약。
Objective To investigate the antitumor drugs the necessity of safety management,provide the basis for safety and reasonable use of anti-tumor drugs.Methods In 236 cases of tumor patients as control group,using the traditional drug safety management mode;another 256 cases as experimental group,using normative antitumor drug safety management mode.Comparison of incidence of two groups of patients with treatment and adverse reaction. Results Patients in the control group the average hospitalization time,categories of drugs and treatment costs are higher than the experimental group;patients in the control group the incidence of adverse reaction was 50.4% in the test group, the incidence rate of adverse reaction was 35.5%,the difference has statistical significance(P<0.05). Conclusion The antitumor drugs on safety management,can significantly shorten the hospitalization time,reduce the cost of treatment,reduce adverse reactions,improve curative effect,achieve real safe and rational drug use.